The stock of Argos Therapeutics Inc (NASDAQ:ARGS) is a huge mover today! The stock decreased 5.03% or $0.25 during the last trading session, hitting $4.72. About 240,856 shares traded hands or 9.04% up from the average. Argos Therapeutics Inc (NASDAQ:ARGS) has risen 11.94% since February 29, 2016 and is uptrending. It has underperformed by 0.28% the S&P500.
The move comes after 9 months negative chart setup for the $209.18 million company. It was reported on Oct, 4 by Barchart.com. We have $4.25 PT which if reached, will make NASDAQ:ARGS worth $20.92 million less.
Analysts await Argos Therapeutics Inc (NASDAQ:ARGS) to report earnings on November, 21. They expect $-0.29 EPS, up 70.10% or $0.68 from last year’s $-0.97 per share. After $-0.48 actual EPS reported by Argos Therapeutics Inc for the previous quarter, Wall Street now forecasts -39.58% EPS growth.
Argos Therapeutics Inc (NASDAQ:ARGS) Ratings Coverage
Out of 4 analysts covering Argos Therapeutics (NASDAQ:ARGS), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Argos Therapeutics has been the topic of 5 analyst reports since November 16, 2015 according to StockzIntelligence Inc. The stock of Argos Therapeutics Inc (NASDAQ:ARGS) has “Outperform” rating given on Monday, November 16 by FBR Capital. The stock has “Buy” rating given by Roth Capital on Tuesday, April 19. The firm has “Market Outperform” rating given on Wednesday, March 9 by JMP Securities. FBR Capital maintained Argos Therapeutics Inc (NASDAQ:ARGS) on Thursday, August 11 with “Outperform” rating. The stock of Argos Therapeutics Inc (NASDAQ:ARGS) earned “Buy” rating by Needham on Tuesday, November 17.
According to Zacks Investment Research, “Argos Therapeutics is a biopharmaceutical company which focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis (TM) technology platform. Argos Therapeutics is based in Durham, United States.”
Insitutional Activity: The institutional sentiment increased to 4.83 in Q2 2016. Its up 3.75, from 1.08 in 2016Q1. The ratio increased, as 1 funds sold all Argos Therapeutics Inc shares owned while 5 reduced positions. 19 funds bought stakes while 10 increased positions. They now own 8.64 million shares or 155.45% more from 3.38 million shares in 2016Q1.
New York State Common Retirement Fund last reported 0% of its portfolio in the stock. Nationwide Fund Advisors reported 6,632 shares or 0% of all its holdings. The Germany-based Deutsche National Bank & Trust Ag has invested 0% in Argos Therapeutics Inc (NASDAQ:ARGS). Goldman Sachs has 3,191 shares for 0% of their US portfolio. Wells Fargo Mn holds 0% or 575 shares in its portfolio. Teachers Advsr last reported 11,307 shares in the company. Kcg Inc last reported 26,554 shares in the company. California State Teachers Retirement holds 0% of its portfolio in Argos Therapeutics Inc (NASDAQ:ARGS) for 22,361 shares. Blackrock owns 533 shares or 0% of their US portfolio. Moreover, Exchange Management has 0% invested in Argos Therapeutics Inc (NASDAQ:ARGS) for 1,000 shares. Schwab Charles Inv Mngmt accumulated 22,200 shares or 0% of the stock. The Utah-based Wasatch Advisors has invested 0.22% in Argos Therapeutics Inc (NASDAQ:ARGS). Geode Mngmt Ltd has invested 0% of its portfolio in Argos Therapeutics Inc (NASDAQ:ARGS). Barclays Public Ltd Com reported 3,303 shares or 0% of all its holdings. The Illinois-based Hightower Ltd Liability Company has invested 0% in Argos Therapeutics Inc (NASDAQ:ARGS).
Insider Transactions: Since August 19, 2016, the stock had 6 insider purchases, and 0 insider sales for $1.43 million net activity. The insider Pharmstandard International S.A. bought 16,977 shares worth $81,150.
More recent Argos Therapeutics Inc (NASDAQ:ARGS) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on March 04, 2012. Also Reuters.com published the news titled: “BRIEF-Russia’s Pharmstandard invests in Argos Therapeutics Inc” on March 24, 2016. Globenewswire.com‘s news article titled: “Dr. Richard D. Katz Joins Argos Therapeutics as Chief Financial Officer” with publication date: July 11, 2016 was also an interesting one.
ARGS Company Profile
Argos Therapeutics, Inc. (Argos), incorporated on May 8, 1997, is an immuno-oncology company. The Firm is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s product candidates include AGS-003 and AGS-004.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.